GCNT3 and pancreatic intraductal papillary-mucinous neoplasm: During the investigation of intraductal papillary mucinous neoplasms (IPMN), an analysis revealed an increase in mucin O-glycosylation pathways throughout IPMN progression and revealed that tantalate can target GCNT3 for mucin regulation and that combining tantalates with chemotherapy enhances immune infiltration, leading to improved therapeutic efficacy 136.